Pathology and Clinical Laboratory Medicine: Industry Report

Summary

Pathology and clinical laboratory medicine sits at the center of diagnosis. One review reports that more than 70% of patient diagnoses are made because of a laboratory test ⁶. Market research firms size the global market at very different levels, so no reconciled revenue figure is available ⁷⁸. Workforce strain is the most consistent finding. A US study found 16 of 17 laboratory medicine sub-disciplines had double-digit vacancy rates ². In the UK, only 5% of pathology survey respondents said all clinical demand was met within contracted hours ⁴. Digital pathology and AI are advancing, but only four FDA-approved whole-slide image cancer AI solutions had been identified ¹². The main risks are staff shortages, an ageing specialist workforce, uneven accreditation and missing data on access, prices and turnaround times. The outlook points to continued demand growth against constrained capacity, which makes retention, training and digital workflow choices central for providers and suppliers.

Key findings

1. 1

   Diagnostic reliance on laboratory testing is high

   More than 70% of patient diagnoses are reported as made because of a laboratory test, though the pack gives no geography or date for this figure.

   Confidence: Medium
2. 2

   Workforce vacancies are widespread in US laboratory medicine

   A study cited by a peer-reviewed article found 16 of 17 laboratory medicine sub-disciplines with double-digit vacancy rates.

   Confidence: High
3. 3

   UK pathology capacity is stretched and the workforce is ageing

   47% of UK pathologists are aged 50 or over, and only 5% of respondents said all clinical demand is met within contracted hours. Goodwill (unpaid overtime) is the most common way services absorb excess demand.

   Confidence: High
4. 4

   Global market size estimates conflict

   Estimates range from USD 20.0 billion to USD 412.06 billion for different market definitions and firms. No audited global revenue total is available.

   Confidence: Qualitative
5. 5

   AI in digital histopathology is still emerging

   Only four FDA-approved whole-slide image cancer AI solutions were identified, and FDA draft guidance on AI-enabled devices is not yet final.

   Confidence: Medium
6. 6

   Accreditation to ISO 15189 is uneven across settings

   In Croatia, 8 of 180 medical biochemistry laboratories were accredited. In Ghana, 15 public laboratories entered a readiness program, and none had proceeded to accreditation by the article's account.

   Confidence: Medium

11. Industry definition and scope

This report covers pathology and clinical laboratory medicine: the laboratory and specialist services that examine specimens to support diagnosis, monitoring and treatment decisions. The term covers pathologists who interpret results, laboratory professionals who perform testing, and the providers and suppliers that run or equip these services.

Terminology varies across sources. Market research uses the labels pathology services ⁷ and pathology laboratories ⁸, which overlap but are not identical. The ISO 15189 standard defines requirements for medical laboratories as a whole ¹³. Where a source does not define its scope, this report says so rather than assuming a boundary.

Geographic scope is global for market figures. Workforce evidence is drawn from the United States, the United Kingdom and Italy, and accreditation examples come from Croatia, Ghana and the United Kingdom. The reporting period is the latest available data in the source pack. Some sources are undated in the pack, and this report does not infer timing for them.

Definitions are descriptive. Where a source does not define pathology or laboratory boundaries, none are inferred.

22. Market size, structure and value chain

Market research firms estimate the global pathology services market at about USD 33.78 billion, with a forecast of USD 47.79 billion at a 7.2% compound annual growth rate ⁷. A separate estimate for pathology laboratories puts the global market at USD 412.06 billion, forecast to reach USD 896.19 billion at an 8.08% compound annual growth rate ⁸. These figures are estimates and forecasts, not audited totals, and they describe different segments.

The gap is large. The same source notes that another research firm sizes the pathology laboratories market at USD 20.0 billion ⁸. This report does not reconcile these figures and treats none of them as a verified market size. Growth drivers cited by market research include precision medicine and AI-powered digital pathology adoption ⁷, which are forecasts rather than observed outcomes.

The value chain runs from specimen collection and laboratory testing through pathologist interpretation and reporting to clinical decisions. Revenue models include fee-for-service testing and contracted hospital or health-system partnerships. Public laboratories, private operators and community settings all sit in this chain, but the pack has no verified split of service volumes or spending among them.

Company results give observed evidence of scale. Quest Diagnostics reported full-year net revenues of USD 11,035 million, up 11.8% from the prior year, and guided to revenues between USD 11.70 billion and USD 11.82 billion for the next year, with a midpoint of USD 11.76 billion ⁹. Company figures are self-reported and cover one large US-headquartered provider, so they do not describe the whole market.

• Global pathology services market size (estimate) 33.78USD billion Estimate Global, Latest available data [7]
• Global pathology services market forecast 47.79USD billion Forecast Global, Forecast period stated by source [7]
• Global pathology laboratories market size (estimate) 412.06USD billion Estimate Global, Latest available data [8]
• Global pathology laboratories market forecast 896.19USD billion Forecast Global, Forecast period stated by source [8]

Two market research sources are shown side by side because they disagree. The gap is reported rather than resolved.

33. Customers, demand and adoption

Customers include clinicians who order tests, patients who receive results, hospitals and health systems that buy services, and payers. The pack gives little direct evidence on purchasing criteria. Speed, accuracy and contracted capacity are implied by the UK survey, where respondents reported that demand often exceeds contracted hours ⁴, but the pack does not rank buyer priorities.

Demand is rising. A peer-reviewed article reports that improved sensitivity and affordability of molecular testing have increased laboratory test demand and added pressure on workforce capacity in the United States ². Quest reported organic requisition volume growth of 3.9% in the third quarter, with total requisition volume growth of 12.5% including acquisitions ¹⁰. The gap between organic and total growth shows that acquisitions drove much of the reported increase.

In Italy, pathologists report rising workload per case and per volume, which affects turnaround times. The article describes this qualitatively and gives no turnaround benchmark ⁵. Advances in personalized medicine and molecular diagnostics add complexity and time per case ⁵.

Barriers to access include capacity limits. The UK census found that only 5% of respondents could meet all clinical demand within contracted hours, and goodwill overtime is the most common response ⁴. Data on waiting times, prevalence linked to pathology demand, equity and geographic access are not available in the pack. Without these, the report cannot measure access gaps directly.

• UK pathology respondents able to meet all clinical demand within contracted hours 5percent of respondents Observed United Kingdom, Latest available data [4]
• Patient diagnoses made because of a laboratory test 70percent (lower bound as stated) Observed Not stated, Not stated [6]

Demand evidence is company and survey based. No national waiting-time or prevalence statistics were available in the pack.

44. Competitive landscape and key players

Providers fall into a few types: large national or multinational diagnostic laboratory companies, equipment and digital pathology suppliers, hospital and public laboratories, and partnerships between providers and health systems. The pack does not give market share or concentration data, so this report cannot measure concentration or rank competitors.

Quest Diagnostics is a US-headquartered diagnostic laboratory company. Its reported revenue and guidance show scale and a business model based on testing volume ⁹. Its partnership with Corewell Health created a joint venture to provide lab services in Michigan ¹⁰. Company reports describe the company's own performance and strategy, so they are useful for scale but not for independent comparison.

Roche Diagnostics supplies digital pathology systems. Its whole-slide imaging system received an additional FDA 510(k) clearance for the VENTANA DP 600 scanner ¹¹. The clearance supports the system's intended use to aid pathologists in reviewing digital images of scanned tissue slides ¹¹. This is a regulatory clearance and a vendor description, not evidence of clinical performance or of installed-base adoption.

Public and private providers differ in accreditation. In Croatia, six of the eight accredited medical biochemistry laboratories were public and two were private ¹⁵. Public laboratories in Ghana face barriers to accreditation ¹⁴. No source gives a verified comparison of quality, cost or waiting times between public, private and community providers.

• Quest Diagnostics full-year net revenues 11035USD million Observed Global (US-headquartered company), Latest full year reported by company [9]
• Quest Diagnostics revenue guidance midpoint 11.76USD billion Forecast Global (US-headquartered company), Next full year (company guidance) [9]
• Quest Diagnostics organic requisition volume growth 3.9percent Observed Global (US-headquartered company), Third quarter of latest year [10]

Competitive comparison relies on company and regulatory sources. Fair comparison of quality or price requires data the pack does not contain.

55. Technology, operations and workforce

Two technology trends stand out: molecular testing and digital pathology with AI. Rising molecular testing sensitivity and affordability increases test volume ². Digital pathology uses scanned slides for review. Four FDA-approved whole-slide image cancer AI solutions had been identified, so AI in digital histopathology remains in an emerging state ¹². The European review in the same article notes CE-marked solutions, but the pack gives no count for these.

Workforce is the binding constraint. The ASCP reports that about 3,000 more pathologists will be needed in the United States, a forecast ³. ASCP also states that the pathology workforce faces challenges distinct from the broader laboratory professional workforce ³. Most of the 16 sub-disciplines with double-digit vacancy rates are laboratory professional roles, not pathologist roles ², so these two problems need separate responses.

In the UK, 47% of pathologists are aged 50 or over, which points to retirements in the coming decade ⁴. Italian pathologists report that workload per case is rising ⁵. Together these sources suggest that operating models, such as shared testing and digital workflow, may be needed to absorb demand. The pack does not measure productivity gains from digital tools.

Training policy is moving. A bipartisan US bill would expand training grants and loan forgiveness for the laboratory workforce and expand National Health Service Corps eligibility ¹. The bill is a proposal. The pack does not confirm enactment.

• UK pathologists aged 50 or over 47percent Observed United Kingdom, Latest available data (census spotlight) [4]
• Additional US pathologists needed (ASCP estimate) 3000pathologists Forecast United States, Forecast horizon stated by source [3]
• Laboratory medicine sub-disciplines with double-digit vacancy rates 16 of 17sub-disciplines Observed United States, Earlier study period, exact timing not stated [2]
• FDA-approved whole-slide image cancer AI solutions identified 4solutions Observed United States, with European CE-marked review, Search as of publication [12]

Workforce projections are US-specific. UK and Italian evidence is survey and commentary based.

66. Regulation, standards, risk and sustainability

Accreditation is the main quality standard. ISO 15189 is the international standard for medical laboratory quality and competence ¹³. In the United Kingdom, UKAS accreditation to ISO 15189 is stated as a requirement for NHS pathology laboratories ¹³. This is a binding requirement as the source states it, and readers should check the current NHS rules directly.

In the United States, CLIA requirements are described only indirectly in the pack. No CMS or regulator source was retrieved, so this report does not state CLIA obligations or accreditation volumes. In the United States, FDA regulates digital pathology devices through clearances such as the Roche scanner clearance ¹¹. FDA draft guidance on lifecycle management and marketing submissions for AI-enabled devices is a proposal, not a final rule ¹².

Proposed legislation on laboratory workforce training is a proposal in the US ¹. Europe applies CE marking to some AI solutions ¹². The pack gives no evidence on privacy, data protection or patient consent rules for pathology data, and these are not assessed here.

Sustainability and environmental impacts of laboratory operations are not covered by any source in the pack. Operational risks include staff shortages, ageing specialist workforces and uneven accreditation capacity. Regulatory and cost risks cannot be assessed without reimbursement or payer policy data, which the pack does not provide. This report is general industry analysis, not medical, legal, investment or engineering advice.

Jurisdictions are identified separately: the UK for accreditation, the US for FDA clearances and proposed workforce legislation, and the European CE mark for certain AI solutions.

77. Challenges, opportunities and case examples

The main challenges are staffing, capacity and accreditation. In the UK, unpaid overtime absorbs excess demand ⁴. Italian workload is rising ⁵. Accreditation is uneven: in Croatia only 8 of 180 medical biochemistry laboratories were accredited to ISO 15189, with six public and two private ¹⁵. In Ghana, 15 public sector laboratories enrolled in an accreditation-readiness program, and none had proceeded to accreditation by the article's account ¹⁴. Limited accreditation capacity restricts quality assurance for public services.

Opportunities include digital pathology, partnerships and efficient testing. Roche's scanner clearance shows that high-volume digital slide review is being built into US regulatory pathways ¹¹. Quest's joint venture with Corewell Health shows one model for shared laboratory services ¹⁰. Proposed federal training grants could widen the pipeline of laboratory staff ¹.

Case example one: Quest Diagnostics, a US-headquartered provider, reported growing revenues and requisition volumes ⁹¹⁰. Its results show demand for testing at scale, but the pack does not show whether this improves access or outcomes.

Case example two: Roche Diagnostics received an additional FDA clearance for a digital slide scanner ¹¹. This supports adoption in principle, but installed-base data are not available.

Case example three: Croatia and Ghana illustrate the accreditation gap in different settings ¹⁵¹⁴. Comparable market data for these examples are not available, so the report does not estimate their economic value.

• Croatian medical biochemistry laboratories accredited to ISO 15189 8 of 180laboratories Observed Croatia, Survey context, earlier period [15]

Examples are drawn from company, regulatory and peer-reviewed sources in the pack. Comparable market data are not available for them.

88. Outlook and strategic implications

In the near term, the most likely scenario is continued demand growth against constrained capacity. Molecular testing and personalized medicine add workload ²⁵, and the UK and US workforce data show limited headroom ⁴². Providers that rely on overtime or unfilled roles face continued strain.

Over the medium term, growth forecasts from market research are high, at 7.2% and 8.08% a year ⁷⁸, but these numbers are unreconciled. AI-supported digital pathology may expand if regulators continue to clear products ¹¹¹², although only four FDA-approved WSI cancer AI solutions had been identified ¹². Training policy may matter if the proposed US bill is enacted ¹, but this is uncertain.

Practical implications are clearer than market size. Providers should plan workforce retention and training, and suppliers should support evidence on clinical performance and adoption. Payers and policymakers need data on waiting times, access and costs, which the pack does not provide. Accreditation programs may need support where uptake is low ¹⁴¹⁵.

Outlook is qualitative because numerical forecasts conflict or lack the scope needed for pathology services.

99. Conclusion

Pathology and clinical laboratory medicine is central to diagnosis, and demand is rising against limited workforce capacity. The most defensible conclusions are that vacancies and ageing are widespread, that digital AI remains early, and that market size figures are too inconsistent to rely on without better data.

Conclusion summarises the report and does not add new evidence.

How this was built

Sources

1. 1

   Medical Laboratory Personnel Shortage Relief Act reintroduced (Dark Daily news report)

   Dark Daily News report

   darkdaily.com
2. 2

   Addressing the Clinical Workforce Shortage by Retaining the Tenured Laboratory Professionals

   Paul Z. Chiou and Lotte Mulder (journal authors) Peer-reviewed

   pmc.ncbi.nlm.nih.gov
3. 3

   ASCP Deepens Commitment to Pathologist Workforce Development

   American Society for Clinical Pathology Industry association

   ascp.org
4. 4

   The Royal College of Pathologists Workforce Census Spotlight (via The Pathologist)

   Royal College of Pathologists, reported by The Pathologist Industry association

   thepathologist.com
5. 5

   The shrinking workforce of pathologists: implications for healthcare and possible solutions

   Authors in Italian journal (Pathologica, letter) Peer-reviewed

   pmc.ncbi.nlm.nih.gov
6. 6

   Laboratory medicine and the hidden crisis of COVID-19 workforce shortages in clinical microbiology

   Journal of Clinical Microbiology authors (PMC) Peer-reviewed

   ncbi.nlm.nih.gov
7. 7

   Pathology Services Market Report

   The Business Research Company Market research

   thebusinessresearchcompany.com
8. 8

   Pathology Laboratories Market Size, Share, and Trends

   Precedence Research Market research

   precedenceresearch.com
9. 9

   Quest Diagnostics Reports Fourth Quarter and Full Year Financial Results

   Quest Diagnostics Incorporated Company report

   newsroom.questdiagnostics.com
10. 10

    Quest Diagnostics Reports Third Quarter Financial Results

    Quest Diagnostics Incorporated Company report

    newsroom.questdiagnostics.com
11. 11

    Roche Digital Pathology Dx receives additional FDA 510(k) clearance for VENTANA DP 600 scanner

    Roche Diagnostics Company report

    diagnostics.roche.com
12. 12

    Translational AI in whole-slide image cancer histopathology: state of the art and regulatory-approved solutions

    Frontiers in Digital Health authors Peer-reviewed

    frontiersin.org
13. 13

    ISO 15189 Accreditation: Requirements, Audits, and How It Differs from CLIA and ISO 17025

    CASRAI Standard

    casrai.org
14. 14

    Challenges with the pursuit of ISO 15189 accreditation in a public health laboratory in Ghana

    Authors in PMC (public health laboratory, Ghana) Peer-reviewed

    ncbi.nlm.nih.gov
15. 15

    Croatian ISO 15189 accreditation survey of medical biochemistry laboratories

    Authors in PMC (Croatia) Peer-reviewed

    ncbi.nlm.nih.gov